AIxCrypto Holdings (AIXC) Q4 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2025 earnings summary
7 Aug, 2026Executive summary
Completed strategic realignment, focusing on AI-enabled real-world asset (RWA) tokenization and embodied AI infrastructure, discontinuing non-core platforms and reducing operational complexity.
Closed $41M PIPE financing and rebranded in November 2025, with significant capital allocated to digital asset treasury and infrastructure initiatives.
No material revenue generated from new platforms to date; company remains in early commercialization phase.
Financial highlights
Net loss for 2025 was $16.97M, compared to $6.26M in 2024, driven by higher G&A expenses and credit loss expense.
General and administrative expenses rose to $8.8M (from $4.2M), mainly due to increased consulting and investor relation fees.
Research and development expenses dropped to $0.18M (from $1.2M) due to funding constraints.
Credit loss expense on short-term notes receivable increased to $4.2M, reflecting higher risk on Marizyme notes.
Net loss on digital assets was $3.6M in 2025; no such losses in 2024.
Cash and equivalents at year-end 2025 were $19.3M; accumulated deficit reached $140M.
Outlook and guidance
Substantial doubt exists about ability to continue as a going concern without additional funding.
Company expects continued net losses and negative cash flow from operations in the near term.
Strategic focus is on scaling RWA tokenization and EAI platforms, with revenue expected from structuring, licensing, and ecosystem participation as commercialization progresses.
Latest events from AIxCrypto Holdings
- RoboShare launch prioritized as Q2 expenses drop 32%, but net loss and liquidity risks remain.AIXC
Q2 2026 - Net loss narrowed, but severe liquidity and going concern risks persist despite new capital raised.AIXC
Q4 2024 - Raising up to $4M for cancer drug development, with high dilution and Nasdaq delisting risk.AIXC
Registration filing - Clinical-stage cancer drug developer seeks up to $4M via equity offering amid financial risks.AIXC
Registration filing - Cancer therapeutics firm seeks up to $1.8M via share/warrant offering amid high financial risk.AIXC
Registration filing - Liquidity crisis persists as cash runs low, with urgent need for financing to avoid delisting.AIXC
Q1 2024 - Cancer drug developer seeks up to $3.7M via share/warrant offering amid Nasdaq delisting risk.AIXC
Registration filing - Net loss narrowed, but liquidity and going concern risks remain acute amid ongoing cash burn.AIXC
Q3 2024 - Severe liquidity challenges persist as net loss grows and cash reserves dwindle, with going concern doubts.AIXC
Q1 2025